Articles On Memphasys (ASX:MEM)

Memphasys (MEM) has enrolled and treated the first couple under a clinical study trialling the safety and performance of its Felix device The study is being conducted with reproductive and fertility services company Monash IVF Group and w...

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

Australian reproductive biotechnology company Memphasys is taking advantage of the worldwide easing of travel rules to turbocharge its trademarked Felix System into global IVF markets.

Neurotech says its cannabis strain NTI164 demonstrates strong results when combined with Diclofenac Memphasys prepares for a pre-submission meeting with the US FDA for its sperm separation tech, the Felix System Neurotech reports positive...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Emerging markets index ends flat ASX200 0.5 higher Chinese economy hit by COVID-lockdowns   Anaemic data out of China has taken the fun out of Monday here in Sydney. April retail sales fell more than 11% year on year, almost twice what wa...

Emerging markets index ends flat ASX200 0.5 higher Chinese economy hit by COVID-lockdowns   Anaemic data out of China has taken the fun out of Monday here in Sydney. April retail sales fell more than 11% year on year, almost twice what wa...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

It’s been an emotional ride for fans of the ASX200 (XJO) which, alongside the Emerging Companies (XEC) index, (down 0.6%) gave up its early gains in a topsy-turvy Monday session. Just after the close, the XJO was weepingly flat – well, up 0...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

The ASX 200 index has closed 1% higher on Monday, while the ASX Emerging Companies (XEC) index shed earlier gains to finish down 0.1%. Disappointing, really. It shoulda been a day for the little guys. Asia was mixed. Although not the Hong K...

Trailblazing biotech Memphasys has achieved a crucial step in the rollout of its IVF sperm separation technology after winning a draft ISO for its quality management system for manufacturing medical devices.

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the majors underperformed the benchmark S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBJD), whereas many small-cap names came thro...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Memphasys has landed the first sale of its revolutionary trademarked Felix bio-separation technology placed by a women’s centre in Coimbatore, India which will be the first to use the system for clinical IVF.

Memphasys is rapidly hurtling towards commercialising with its “Felix” IVF reproductive technology. Clinical trials are set to commence at four Monash IVF Australian clinics soon.

Investing in ASX biotech shares was an underwhelming affair in November. As a basket, the sector lagged key benchmarks, and many names saw substantial declines in value over the month. Renewed fears from the Omicron COVID-19 variant saw in...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le...

For the second month in a row the ASX was hit by a major sell-off in the last few days of the month and it took the bourse from what was then a 0.5% gain to a 1.56% loss in November. Just when we thought we were out of the worst of COVID, w...

Memphasys has successfully collected data from approximately 240 horse inseminations to test its novel “SAMSON” stallion fertility diagnostic device that may cut sperm quality diagnosis times to 15 minutes.

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

The Australian bourse recouped most of yesterday’s losses despite tech stocks dropping again, this time by 3.49%. The ASX 200 rose 0.78%, closing at 7,411 points, with the gains driven by the resources and energy sectors, which gained 2.3%...

Reproduction biotechnology and bio-separations company Memphasys (MEM) completes the maiden sale of Felix The sale was made to Diagens Biotechnology, which is a Chinese company that manufacturers and distributes human reproduction product...

The ASX 200 Health Index (XHJ) is down by 0.35% at the time of writing, compared to the broader index which is down by 0.80%. A private fund owned by the Forrest family, Tattarang, has invested $5m or 7.3% stake in cannabis company, Emyria...

The hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector from falling today. The ASX 200 finished 0.67% down at 7,420 points. All sectors were down except tech, which gained 0.18%. In contrast, mo...

The benchmark S&P/ASX 200 index (ASX: XJO) has slipped 0.75% into the red today at 7,414 points. The S&P/ASX 200 Healthcare Index (ASX: XHJ) is leading the broad market’s losses and has sunk 1.12% at the time of writing. Despite t...

Local stocks posted a solid session on Wednesday ahead of this week’s main event on global markets later tonight — the US Fed’s latest policy decision. After plenty of forward guidance, the Fed is expected to formally announce the taper of...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Local stocks struggled for traction in Wednesday trade, as the major indexes drifted sideways following a weak lead out of the US. Banks and energy stocks were up, offsetting falls in resources and consumer staples. There were few major cat...

Wall Street inches lower overnight All three US stock market indexes finished slightly lower overnight to close out the month. The Dow Jones fell by 0.11%, the S&P 500 by 0.13%, and tech heavy Nasdaq by 0.04%. European shares also fell...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

ShareCafeMemphasys Taking on One of Humanity’s Most Pressing Issues Humanity has a profound demographic problem and it’s not overpopulation. On the contrary, men are becoming more infertile and the quality of their sperm is deteriorating, l...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Unlisted company Ellume is making headlines again with reports claiming Australian governments are being lobbied to approve the use of at-home rapid COVID-19 tests. While it would be the dream of many investors to see Ellume debut on the A...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

The Full 180 is a fortnightly look at ASX capital raisings. We are entering our fourth week (or so) of a quiet/consolidation period for capital raisings. We are chugging along at a pace of four to six share placements per day, with volumes...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Large and small caps had diverging fates on the ASX today with the former closing 0.32 per cent down from yesterday at 7,093 points while the ASX Emerging Companies Index rose 1.21 per cent to close at 2,159. The various ASX sectors were al...

The ASX notched up gains today despite one of the biggest IPOs this year dropping on debut. The ASX 200 rose 0.98 per cent to close at 7,115 and every sector was in the green except utilities. The best were consumer discretionaries, health...